Posted by Michael Wonder on 12 Aug 2021
Second U.S. FDA breakthrough device designation granted to CytoSorbents' DrugSorb-ATR anti-thrombotic removal system adding the removal of market leading direct oral anti-coagulants during urgent cardiothoracic surgery
12 August 2021 - FDA breakthrough designation granted to CytoSorbents' DrugSorb-ATR for removal of apixaban and rivaroxaban to reduce the risk of serious bleeding in urgent cardiothoracic surgery.
CytoSorbents Corporation announced that the Company has been granted a second breakthrough device designation for its DrugSorb-ATR anti-thrombotic removal system by the U.S. FDA.
